


Results from the Phase 3 RAPiDe-3 Trial: Efficacy and Safety of Oral Deucricitbant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks

Paola Triggianese¹, Philip H. Li², Adil Adatia³, Mauro Cancian⁴, Marcin Stobiecki⁵, Anna Valeríeva⁶, Anete S. Grumach⁷, William R. Lumry⁸, Daniel F. Soteres⁹, Nicholas Brodzski¹⁰, Natalia L. Fili¹¹, Roman Haki¹², Hye-Ryun Kang^{13,14,15,16}, Gul Karakaya¹⁷, Birger Kränke¹⁸, H. Henry Li¹⁹, Jonny Peter^{20,21}, Andreas Recke²², Raffi Tachdjian²³, Andrea Zanichelli^{24,25}, John Anderson²⁶, Emel Aygören-Pürsün²⁷, Timothy J. Craig^{28,29}, Henriette Farkas³⁰, Francesco Giardinò³¹, Pedro Giavina-Bianchi³², Suejong Kim³³, Tamar Kinaciyan³⁴, Inmaculada Martínez-Saguer³⁵, Francesca Perego³⁶, Karl V. Sitz³⁷, Maria Staveks³⁸, H. James Wedner³⁹, Rafael H. Zaragoza-Urdaz³⁹, Ricardo D. Zwienen⁴⁰, Aslı Gelincik⁴¹, Francesco Arcoleo⁴², Rand Arnaout⁴³, Alan P. Baptist⁴⁴, Régis de Albuquerque Campos⁴⁵, Anthony D. Dorr⁴⁶, Mariana Paes Leme Ferranti⁴⁷, Atsushi Fukunaga⁴⁸, Delphine Gobert⁴⁹, Padmalal Gurugama⁵⁰, Michihiro Hide⁵¹, David I. Hong⁵², Eisuke Inage⁵³, Joshua S. Jacobs⁵⁴, Constance H. Katelaris⁵⁵, Lucy Leeman⁵⁶, Ramón Leonart⁵⁷, Markus Mager^{58,59}, Michael E. Manning⁶⁰, Satoshi Mano⁶¹, Seido Ooka⁶², Cristina J. Ramos⁶³, Jinzhong Liu⁶⁴, Li Zhu⁶⁴, Joan Mendivil⁶⁵, Umar Katbeh⁶⁶, Giorgio Giannattasio⁶⁶, Rafael Crabb⁶⁶, Ming Yu⁶⁴, Anne Lesage⁶⁷, Peng Lu⁶⁴, Danny M. Cohn⁶⁸, Marc A. Riedl⁶⁹

¹University of Rome Tor Vergata, Rome, Italy; ²Queen Mary Hospital, University of Hong Kong, Hong Kong; ³University of Alberta, Edmonton, AB, Canada; ⁴Azienda Ospedale Università di Padova, Padua, Italy; ⁵Jagiellonian University Medical College, Kraków, Poland; ⁶Medical University of Sofia, Sofia, Bulgaria; ⁷Centro Universitario FMABC, São Paulo, Brazil; ⁸FAARA Research Center, Dallas, TX, USA; ⁹Asthma & Allergy Associates and Research Center, P.O. Colorado Springs, Colorado, USA; ¹⁰University of Colorado Health Sciences Center, Aurora, CO, USA; ¹¹Children's Hospital, Skåne University Hospital, Lund, Sweden; ¹²Hospital Público Materno Infantil, Salta, Argentina; ¹³St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; ¹⁴Seoul National University College of Medicine, Seoul, South Korea; ¹⁵Seoul National University Hospital, Seoul, South Korea; ¹⁶Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, South Korea; ¹⁷Korean Drug Allergy Research Consortium, Seoul, South Korea; ¹⁸Hacettepe University Faculty of Medicine, Ankara, Türkiye; ¹⁹Medical University of Graz, Graz, Austria; ²⁰Institute for Asthma and Allergy, Chevy Chase, MD, USA; ²¹Groote Schuur Hospital, Cape Town, South Africa; ²²University of Cape Town and Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa; ²³University of Lübeck, Lübeck, Germany; ²⁴University of California at Los Angeles, Los Angeles, CA, USA; ²⁵Università degli Studi di Milano, Milan, Italy; ²⁶AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA; ²⁷Goethe University Frankfurt, Frankfurt am Main, Germany; ²⁸Penn State University, Hershey, PA, USA; ²⁹Vinmec-VinUni Institute of Immunology, Vinmec Hospital, Times City, Vietnam, and Vin University, Hanoi, Vietnam; ³⁰Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary; ³¹I.A.O.U. Policlinico "G. Rodolfo-San Marco", Catania, Italy; ³²Prof. Livre Docente Associado - Disciplina de Imunologia Clínica e Alergia da FMUSP, Visiting Professor at Harvard Medical School 2012-14, Editor in Chief of *Arquivos de Asma, Alergia e Imunologia*, Diretor da World Allergy Organization, São Paulo, Brazil; ³³School of Medicine, Kyungpook National University Hospital, Daegu, South Korea; ³⁴Medical University of Vienna, Vienna, Austria; ³⁵HZRM Hämostaseologie Zentrum Rhein Main GmbH, Frankfurt, Germany; ³⁶Istituto Clinico Scientifici Maugeri IRCCS, Milan, Italy; ³⁷Acuro Research, Inc., Little Rock, AR, USA; ³⁸Washington University School of Medicine, St. Louis, MO, USA; ³⁹University Pediatric Hospital, San Juan, Puerto Rico; ⁴⁰Hospital Universitario Austral, Buenos Aires, Argentina; ⁴¹Istanbul University, Istanbul, Türkiye; ⁴²AOR Villa Sofia-Cervello, Palermo, Italy; ⁴³King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; ⁴⁴Henry Ford Health System, Detroit, MI, USA; ⁴⁵Ensinio e Terapia de Inovação Clínica AMO, Salvador, Bahia, Brazil; ⁴⁶Barts Health NHS Trust, London, UK; ⁴⁷Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; ⁴⁸Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan; ⁴⁹Sorbonne Université, Médecine Interne, Centre de Référence des Angioedèmes à Kinines, Hôpital Saint-Antoine, AP-HP, Paris, France; ⁵⁰Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; ⁵¹Hiroshima University and Hiroshima City Hospital Organization, Hiroshima, Japan; ⁵²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; ⁵³Juntemo University Faculty of Medicine, Tokyo, Japan; ⁵⁴Allergy and Asthma Clinical Research, Walnut Creek, CA, USA; ⁵⁵Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia; ⁵⁶University Hospitals Plymouth NHS Trust, Plymouth, UK; ⁵⁷Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; ⁵⁸Institute of Allergy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ⁵⁹Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergy, Berlin, Germany; ⁶⁰Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; ⁶¹Juntemo University Hospital, Tokyo, Japan; ⁶²St. Marianna University School of Medicine Hospital, Kanagawa, Japan; ⁶³FDI Clinical Research, San Juan, Puerto Rico; ⁶⁴Pharvaris Inc., Lexington, MA, USA; ⁶⁵Pharvaris GmbH, Zug, Switzerland; ⁶⁶RC Consultancy, Bassins, Switzerland; ⁶⁷GrayMatters Consulting, Schilde, Belgium; ⁶⁸Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ⁶⁹University of California San Diego, La Jolla, CA, USA

Key takeaways

Results from the pivotal RAPiDe-3 trial for the treatment of attacks in multiple types of hereditary angioedema provide further evidence on the rapid and sustained efficacy, safety, and tolerability of the orally administered bradykinin B2 receptor antagonist deucricitbant immediate-release (IR) capsule. This trial met its primary and all 11 secondary efficacy endpoints.^a



This presentation includes data for an investigational product not yet approved by regulatory authorities.

Background


- Hereditary angioedema (HAE):** a bradykinin-mediated condition with painful swelling attacks affecting multiple locations in the body.¹
- Unmet need:** an unmet need remains for additional orally administered treatments combining ease of administration, rapid and sustained effects, and a well-tolerated safety profile.^{2,3}
- Oral deucricitbant:** a selective bradykinin B2 receptor antagonist under development for both prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks.⁴⁻¹⁰

Objective

To assess the efficacy, safety, and tolerability of oral deucricitbant immediate-release (IR) capsule for on-demand treatment of attacks in adolescents and adults with HAE, including participants with HAE with normal C1 inhibitor (HAE-nC1INH).

Methods

Figure 1. RAPiDe-3 trial design



ePRO, electronic patient-reported outcome; HAE, hereditary angioedema; IR, immediate-release; OLE, open-label extension; R, randomization. ^aAdolescent participants received a non-attack dose for pharmacokinetic sampling at Day 1 visit prior to randomization. ^bData from end-of-study visit could be used to qualify the participant for an LTP study with deucricitbant. ^cRollover to the OLE was optional. Riedl MA, et al. *Lancet*. 2026; doi: 10.1016/S0140-6736(26)01296-1.

- RAPiDe-3 (NCT06343779)*:** a global, Phase 3, randomized, double-blind, placebo-controlled, crossover trial.
- Participants:** adolescents (aged ≥12 to <18 years) and adults (aged ≥18 to ≤75 years) with HAE-nC1INH type 1 or 2, or HAE-nC1INH. Participants on long-term HAE prophylaxis were also enrolled.
- Study drugs:** participants self-administered deucricitbant IR capsule 20 mg or placebo to treat two qualifying attacks in a crossover design. Qualifying attacks were defined as either a non-laryngeal attack with at least one symptom item score of ≥20 on the Angioedema Symptom Rating scale (AMRA) assessment, or a non-severe laryngeal attack without breathing difficulties or stridor.
- Analysis sets:** primary efficacy analysis included all randomized participants who had two attacks treated with study drug (one per period) in the 2x2 crossover design. Safety analysis included all participants who received ≥1 dose of study drug.

Table 1. Selected efficacy^a and safety endpoints

Endpoint	Instrument	Definition
Primary endpoint		
Time to onset of symptom relief	PGI-C	Time to a PGI-C rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment
Secondary endpoints		
Proportion of attacks achieving onset of symptom relief	PGI-C	Proportion of study-drug treated attacks achieving a PGI-C rating of at least "a little better" at 4 hours post-treatment
Time to substantial symptom relief	PGI-C	Time to a PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment
Time to reduction in attack severity	PGI-S	Time to a ≥1-level reduction in PGI-S score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment
Time to complete symptom resolution	PGI-S	Time to PGI-S rating of "none" within 48 hours post-treatment
Use of conventional on-demand treatment as rescue medication	–	Proportion of study-drug treated attacks using conventional on-demand treatment as rescue medication to treat an attack within 24 hours post-treatment
Safety endpoint		
TEAEs and serious TEAEs	–	TEAE defined as an adverse event from the first study drug administration through the end-of-study visit

PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity; TEAE, treatment-emergent adverse event. ^aThe primary and 5 of 11 hierarchical order-ranked secondary endpoints.

Results

- A total of 134 eligible participants (10 [7.5%] adolescents, 4 [3.0%] with HAE-nC1INH) were enrolled and randomized at 59 sites across 24 countries on 6 continents.
- The primary efficacy analysis set included 88 participants with paired attacks; 113 participants had ≥1 attack treated with study drug.
- Demographics and baseline characteristics were generally balanced across treatment groups.

Table 2. Participant demographics and baseline disease characteristics


Participant characteristics	All randomized participants (N=134)
Age in years, mean (SD)	39.0 (14.7)
≥12 to <18, n (%)	10 (7.5)
≥18 to <65, n (%)	116 (86.6)
≥65, n (%)	8 (6.0)
Sex: Female, n (%)	76 (56.7)
BMI, mean (SD)	26.5 (5.9)
Race, n (%)	
White	93 (69.4)
Asian	19 (14.2)
Black or African American	10 (7.5)
American Indian or Alaska Native	1 (0.7)
Other	7 (5.2)
Not reported	4 (3.0)
Region, n (%)^a	
Europe	56 (41.8)
Rest of world	40 (29.9)
North America	38 (28.4)
Years since HAE diagnosis, mean (SD)	17.7 (13.0)
Number of attacks within 3 months before screening, mean (SD)	4.4 (3.3)
HAE type, n (%)	
HAE-C1INH type 1	118 (88.1)
HAE-C1INH type 2	10 (7.5)
Unspecified HAE-C1INH type 1 or 2	2 (1.5)
HAE-nC1INH ^b	4 (3.0)
Current LTP use, n (%)^c	31 (23.1)

BMI, body mass index; C1INH, C1 inhibitor; HAE, hereditary angioedema; LTP, long-term prophylaxis; nC1INH, normal C1 inhibitor; SD, standard deviation. ^aGeographic region of North America included Canada, Puerto Rico, United States of America; Europe included Austria, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom; Rest of world included Argentina, Australia, Brazil, Hong Kong, Japan, Saudi Arabia, South Africa, South Korea, Turkey. ^bIncluded participants with nC1INH associated with a documented genetic variant. ^cLTP medication included lanadelumab (13 [9.7%]), bevontrastat (8 [6.0%]), c1 esterase inhibitor (6 [4.5%]), and other (4 [3.0%]).

Results


Efficacy

Figure 2. Primary endpoint: Significantly faster onset of symptom relief with deucricitbant compared with placebo^{a,b}




CI, confidence interval; PGI-C, Patient Global Impression of Change. ^aIf the event of interest was not achieved within the pre-specified timeframe, the attack was right censored at the last observation before the upper end of the data entry window. For attacks with rescue medication use, they were treated as right censored at the upper end of the data entry window. ^bPGI-C rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment.

Figure 3. Significantly higher proportion of attacks shown to achieve onset of symptom relief at 4 hours^a with deucricitbant compared with placebo



PGI-C, Patient Global Impression of Change. ^aOnset of symptom relief was considered achieved at 4 hours if for an attack, the last or the second-to-last available value of PGI-C prior to 4 hours post-treatment achieved "a little better" or higher response ("better" or "much better") and was sustained for 2 consecutive timepoints. Attacks with no PGI-C recorded within 4 hours post-treatment were excluded from the analysis, unless there was an intercurrent event for that attack, in which case the attack was considered as not achieving PGI-C "a little better" at 4 hours. ^bNumber of participants with PGI-C data within 4 hours post-treatment.

Figure 4. Secondary endpoints



CI, confidence interval; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^aIf the event of interest was not achieved within the pre-specified timeframe, the attack was right censored at the last observation before the upper end of the data entry window. For attacks with rescue medication use, they were treated as right censored at the upper end of the data entry window. ^bA ≥1-level reduction in PGI-S score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment. ^cPGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment. ^dPGI-S rating of "none" within 48 hours post-treatment.

Figure 5. Majority of deucricitbant-treated attacks shown to achieve efficacy endpoints with a single capsule





Figure 6. More than 80% of deucricitbant-treated attacks were treated with a single capsule and more than 90% did not require rescue medication



Safety

- The only event reported more than once within 3 days post-treatment was fatigue: a single event was reported by 2 participants, one of which was deemed unrelated to treatment by the investigator.
- No adverse events occurring within 3 days post-treatment were assessed as severe or serious, led to treatment discontinuation, or were associated with changes in clinical laboratory, vital signs, or electrocardiogram parameters.

Table 3. Treatment-emergent adverse events occurring within 3 days post-treatment

Adverse events	n (%) ^a	no. of events	n (%) ^a	no. of events	n (%) ^a	no. of events
Any TEAE	0	0	15 (15.0)	17	2 (2.0)	3
Treatment-related TEAEs^d	0	0	5 (5.0)	6	1 (1.0)	1
Any severe TEAE^e	0	0	0	0	0	0
Serious TEAEs	0	0	0	0	0	0
TEAEs leading to study drug discontinuation, study withdrawal, or death	0	0	0	0	0	0

TEAE, treatment-emergent adverse event. N refers to the total number of participants who received ≥1 dose of study drug. Percentage is calculated based on the N in the header; percentage = 100 × n/N where N is the number of participants.

^aAdolescent participants only. ^bDefined as the number of participants with an adverse event that began within 3 days post-treatment of non-attack period and before the next administration of study drug. ^cDefined as the number of participants with an adverse event that started within 3 days post-treatment of attack. ^dOne related TEAE each of dyspepsia, fatigue, lethargy, brain fog, headache, and somnolence in deucricitbant-treated participants, and 1 event of pruritus in placebo-treated participants.

^eAll reported TEAEs were graded 1 (mild) or 2 (moderate) and there were no reported TEAEs graded 4 (life-threatening) or 5 (fatal).

References

- Busse PJ, et al. *N Engl J Med*. 2020;382:1136-48.
- Betschel SD, et al. *Allergy Asthma Clin Immunol*. 2025;21:25.
- Valeríeva A, et al. *Clin Transl Allergy*. 2024;14:e12391.
- Maurer M, et al. *Lancet Haematol*. 2026;13(4):e200-14.
- RAPiDe-2. <https://clinicaltrials.gov/study/NCT05396105>. Accessed October 12, 2026.
- Riedl MA, et al. *Lancet*. 2026; doi: 10.1016/S0140-6736(26)01296-1.
- Aygören-Pürsün E, et al. *Lancet Haematol*. 2026;13(4):e215-26.
- CHAPTER-3. <https://clinicaltrials.gov/study/NCT06669754>. Accessed October 12, 2026.
- CHAPTER-4. <https://clinicaltrials.gov/study/NCT0679881>. Accessed October 12, 2026.
- CREAATE. <https://clinicaltrials.gov/study/NCT07266805>. Accessed October 12, 2026.

COI: P.T.: Abbvie, Biocyst, CSL Behring, KalVista, Takeda; P.H.L.: ADARx Pharmaceuticals, Argo Biopharma, Astria Therapeutics, BioCryst Pharmaceuticals, CSL Behring, Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris, Takeda; A.A.: Astria, BioCryst, CSL Behring, Intellia, Ionis Pharmaceuticals, KalVista, Octapharma, Pendopharm, Pharvaris, Takeda; M.C.: ADARx, BioCryst, Chiesi, CSL Behring, Gentili, KalVista, Menarini, MSD, NeoPharm, Novartis, Otsuka, Pharming, Pharvaris, Sobri, Takeda, UCB; M.Sto.: ARGO Biopharmaceuticals, BioCryst, CSL Behring, Genesis Pharma, KalVista, Pharvaris, Swix, Takeda; A.V.: ADARx, AstraZeneca, Astria, Bulgarian Society of Allergy, Chiesi, CSL Behring, EAACI Angioedema Working Group, Ionis, KalVista Pharmaceuticals, Novartis, Pharming, Pharvaris, Takeda; N.B.: none to report; N.L.F.: Bago, CSL Behring, Pint Pharma, Takeda, Director of HAE committee for AA&E; R.H.: BioCryst, CSL Behring, Genesis Pharma, KalVista, Pharming, Pharvaris, Takeda; H.R.K.: Astria, BioCryst, KalVista, Pharvaris, Takeda; G.K.: CSL Behring, Erkin Ilac, Ionis, Pharvaris, Polifarma, Takeda, Vem Iac; B.K.: Pharvaris; H.H.L.: BioCryst, CSL Behring, Intellia, Ionis, Pharming, Pharvaris, Takeda, Medical Advisory Board US HAAE; J.P.: ADARx, Astria, BioCryst, Intellia, Pharming, Pharvaris, Takeda; A.R.: BioCryst, CSL Behring, Deutsche Forschungsgemeinschaft (DFG), EUDROMMUN Medizinische Labordiagnostika AG, Pierre Fabre Pharma, NeoPharmed Gentili, Novartis, Otsuka, Pharming, Pharvaris, Stallergenes, Swedish Orphan Biovitrum, Otsuka, Takeda; R.T.: ADARx, AstraZeneca, Astria, BioCryst, CSL Behring, GlaxoSmithKline, Grifols, Intellia, Ionis, KalVista, Lilly, Novartis, Pharming, Pharvaris, Takeda; J.A.: Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Otsuka, Pharming, Pharvaris, Takeda; A.P.: Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Otsuka, Pharming, Pharvaris, Takeda; M.M.: Argo, Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Octapharma, Otsuka, Pharming, Pharvaris, Takeda; M.E.M.: AstraZeneca, Astria, BioCryst, Bluebird, Celldex, Cogent, CSL Behring, GlaxoSmithKline, Intellia, Ionis, KalVista, Merck, Novartis, Pharming, Pharvaris, Regeneron, Takeda; Tava S.M.: none to report; S.O.: none to report; C.J.R.: Amgen, GlaxoSmithKline, Pfizer, Pharvaris, Sanofi, Takeda; J.L., L.Z., J.M., U.K., G.S., M.Y., P.L.: employees of Pharvaris, holds stocks in Pharvaris; R.C.: is an employee of RC consultancy and consultant to Pharvaris, holds stocks in Pharvaris; A.L.: is an employee of GrayMatters Consulting and consultant to Pharvaris, holds stocks/stock options in Pharvaris; advisor to Kosa Pharma; D.M.C.: ADARx, Astria Therapeutics, BioCryst, CSL Behring, Gentili NeoPharm, Intellia, Ionis, KalVista, Otsuka, Pharvaris, Takeda, is a Regional Medical Advisory Panel Member for HAE Central Eastern Europe and the Benelux; M.A.R.: ADARx, Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cytel Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda.

Acknowledgments: Medical writing services were provided by Jonny Turner, PhD, of Envision Medical Communications, and funded by Pharvaris.

Adapted/Reproduced from "Oral deucricitbant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial" by Marc A Riedl, Philip H Li, Adil Adatia, et al., 2026, *The Lancet*, published online October 8, 2026, doi: 10.1016/S0140-6736(26)01296-1, licensed under CC BY 4.0.

^aRAPiDe-3 is a Pharvaris-sponsored clinical study. [ClinicalTrials.gov identifier: NCT06343779](https://clinicaltrials.gov/identifiers/NCT06343779).